Biopharmaceutical Research Company (BRC), a Monterey, California-based organization which holds a valid Drug Enforcement Administration (DEA) pharmaceutical cannabis license, in Series A funding raised a total of $20 million. Achari Ventures, Argonautic Ventures, AFI Capital Partners, Self Health America, Delta Emerald Ventures, and several distinguished private equities participated in the round, which Intrinsic Capital Partners spearheaded.
Trulieve becomes the first U.S. cannabis company to trade on the NYSE on June 10.…
From robot canopy scanners to algorithmic breeders to AI-powered dispensary counters, artificial intelligence is remaking…
The latest version of this story comes from Virginia Commonwealth University, where researcher Emanuele Alves…
But there's more to this image than nostalgia and comedy. What you're looking at in…
The league pulled marijuana off its banned list in the new players’ agreement. In the…
In New South Wales, Australia, patients can legally use medical cannabis with a prescription. So…